145 related articles for article (PubMed ID: 36473980)
1. CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response.
Jutzi JS; Marneth AE; Jiménez-Santos MJ; Hem J; Guerra-Moreno A; Rolles B; Bhatt S; Myers SA; Carr SA; Hong Y; Pozdnyakova O; van Galen P; Al-Shahrour F; Nam AS; Mullally A
Leukemia; 2023 Feb; 37(2):359-369. PubMed ID: 36473980
[TBL] [Abstract][Full Text] [Related]
2. Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms.
Ibarra J; Elbanna YA; Kurylowicz K; Ciboddo M; Greenbaum HS; Arellano NS; Rodriguez D; Evers M; Bock-Hughes A; Liu C; Smith Q; Lutze J; Baumeister J; Kalmer M; Olschok K; Nicholson B; Silva D; Maxwell L; Dowgielewicz J; Rumi E; Pietra D; Casetti IC; Catricala S; Koschmieder S; Gurbuxani S; Schneider RK; Oakes SA; Elf SE
Blood Cancer Discov; 2022 Jul; 3(4):298-315. PubMed ID: 35405004
[TBL] [Abstract][Full Text] [Related]
3. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927
[TBL] [Abstract][Full Text] [Related]
4. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
[TBL] [Abstract][Full Text] [Related]
5. Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody.
Tvorogov D; Thompson-Peach CAL; Foßelteder J; Dottore M; Stomski F; Onnesha SA; Lim K; Moretti PAB; Pitson SM; Ross DM; Reinisch A; Thomas D; Lopez AF
EMBO Rep; 2022 Apr; 23(4):e52904. PubMed ID: 35156745
[TBL] [Abstract][Full Text] [Related]
6. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
Edahiro Y; Araki M; Komatsu N
Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673
[TBL] [Abstract][Full Text] [Related]
7. Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities.
Foßelteder J; Pabst G; Sconocchia T; Schlacher A; Auinger L; Kashofer K; Beham-Schmid C; Trajanoski S; Waskow C; Schöll W; Sill H; Zebisch A; Wölfler A; Thomas D; Reinisch A
Leukemia; 2023 Apr; 37(4):843-853. PubMed ID: 36813992
[TBL] [Abstract][Full Text] [Related]
8. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
[TBL] [Abstract][Full Text] [Related]
9. Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.
Merlinsky TR; Levine RL; Pronier E
Clin Cancer Res; 2019 May; 25(10):2956-2962. PubMed ID: 30655313
[TBL] [Abstract][Full Text] [Related]
10. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
Araki M; Yang Y; Masubuchi N; Hironaka Y; Takei H; Morishita S; Mizukami Y; Kan S; Shirane S; Edahiro Y; Sunami Y; Ohsaka A; Komatsu N
Blood; 2016 Mar; 127(10):1307-16. PubMed ID: 26817954
[TBL] [Abstract][Full Text] [Related]
11. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.
Elf S; Abdelfattah NS; Baral AJ; Beeson D; Rivera JF; Ko A; Florescu N; Birrane G; Chen E; Mullally A
Blood; 2018 Feb; 131(7):782-786. PubMed ID: 29288169
[TBL] [Abstract][Full Text] [Related]
12. MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.
Yasuda S; Aoyama S; Yoshimoto R; Li H; Watanabe D; Akiyama H; Yamamoto K; Fujiwara T; Najima Y; Doki N; Sakaida E; Edahiro Y; Imai M; Araki M; Komatsu N; Miura O; Kawamata N
Int J Hematol; 2021 Oct; 114(4):424-440. PubMed ID: 34165774
[TBL] [Abstract][Full Text] [Related]
13. A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.
Kollmann K; Warsch W; Gonzalez-Arias C; Nice FL; Avezov E; Milburn J; Li J; Dimitropoulou D; Biddie S; Wang M; Poynton E; Colzani M; Tijssen MR; Anand S; McDermott U; Huntly B; Green T
Leukemia; 2017 Apr; 31(4):934-944. PubMed ID: 27740635
[TBL] [Abstract][Full Text] [Related]
14. Targeting the CALR interactome in myeloproliferative neoplasms.
Pronier E; Cifani P; Merlinsky TR; Berman KB; Somasundara AVH; Rampal RK; LaCava J; Wei KE; Pastore F; Maag JL; Park J; Koche R; Kentsis A; Levine RL
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429377
[TBL] [Abstract][Full Text] [Related]
15. Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs.
Jutzi JS; Marneth AE; Ciboddo M; Guerra-Moreno A; Jiménez-Santos MJ; Kosmidou A; Dressman JW; Liang H; Hamel R; Lozano P; Rumi E; Doench JG; Gotlib J; Krishnan A; Elf S; Al-Shahrour F; Mullally A
Blood; 2022 Sep; 140(11):1291-1304. PubMed ID: 35763665
[TBL] [Abstract][Full Text] [Related]
16. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
17. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
18. Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.
Pecquet C; Papadopoulos N; Balligand T; Chachoua I; Tisserand A; Vertenoeil G; Nédélec A; Vertommen D; Roy A; Marty C; Nivarthi H; Defour JP; El-Khoury M; Hug E; Majoros A; Xu E; Zagrijtschuk O; Fertig TE; Marta DS; Gisslinger H; Gisslinger B; Schalling M; Casetti I; Rumi E; Pietra D; Cavalloni C; Arcaini L; Cazzola M; Komatsu N; Kihara Y; Sunami Y; Edahiro Y; Araki M; Lesyk R; Buxhofer-Ausch V; Heibl S; Pasquier F; Havelange V; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2023 Feb; 141(8):917-929. PubMed ID: 36356299
[TBL] [Abstract][Full Text] [Related]
19. Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice.
Shide K; Kameda T; Kamiunten A; Ozono Y; Tahira Y; Yokomizo-Nakano T; Kubota S; Ono M; Ikeda K; Sekine M; Akizuki K; Nakamura K; Hidaka T; Kubuki Y; Iwakiri H; Hasuike S; Nagata K; Sashida G; Shimoda K
Blood; 2020 Jul; 136(1):106-118. PubMed ID: 32219445
[TBL] [Abstract][Full Text] [Related]
20. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Camacho L; Fernández-Rodríguez MC; Pairet S; Besses C
Leuk Res; 2016 Sep; 48():11-5. PubMed ID: 27427771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
